This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Kuchel, O. Articles by Shigetomi, S. Search for Related Content PubMed PubMed Citation Articles by Kuchel, O. Articles by Shigetomi, S. Pubmed/NCBI databases Compound via MeSH Substance via MeSH Hazardous Substances DB DOPAMINE L-TYROSINE Medline Plus Health Information High Blood Pressure

Hypertension, Vol 19, 634-638, Copyright © 1992 by American Heart Association

ARTICLES

Defective dopamine generation from dihydroxyphenylalanine in stable essential hypertensive patients

O Kuchel and S Shigetomi
Clinical Research Institute of Montreal, Quebec, Canada.

We studied the metabolic pathways of dihydroxyphenylalanine (DOPA) and dopamine as well as the cardiovascular and renal responses to a single administration of DOPA (500 mg orally) in stable essential hypertension. We found that after DOPA, stable hypertensive patients compared with controls showed more blood pressure decrease without reflex tachycardia, had lower creatinine clearance but a higher fractional excretion of sodium, and had lower plasma renin activity at the height of DOPA action. Hypertensive patients also showed increased plasma DOPA, the ratio of plasma DOPA to dopamine, and the sum of plasma DOPA and 3-O-methyl-DOPA, as well as increased urinary 3-O- methyl-DOPA and the plasma and urine dopamine metabolites 3,4- dihydroxyphenylacetic acid and homovanillic acid. Finally, despite an augmented post-DOPA glomerular load of DOPA, the predominant source of urinary dopamine, the excretion rates of dopamine and its metabolites remained comparable in hypertensive patients to those in control subjects. These data suggest that, in stable hypertensive patients, exogenous DOPA is to a lesser degree decarboxylated to dopamine, which is more rapidly metabolized intraneuronally. Contrasting with this finding are the hyperdopaminergic features, such as hypernatriuresis with renin suppression and excessive blood pressure decline in the absence of reflex tachycardia. They may be due to an upregulation of renal, vascular, and brain dopaminergic receptors secondary to a preexisting dopaminergic deficiency in stable essential hypertension.

This article has been cited by other articles:

				H. Quinones, R. Collazo, and O. W. Moe The dopamine precursor L-dihydroxyphenylalanine is transported by the amino acid transporters rBAT and LAT2 in renal cortex Am J Physiol Renal Physiol, July 1, 2004; 287(1): F74 - F80. [Abstract] [Full Text] [PDF]

				T. Hussain and M. F. Lokhandwala Renal Dopamine Receptors and Hypertension Experimental Biology and Medicine, February 1, 2003; 228(2): 134 - 142. [Abstract] [Full Text] [PDF]

				M. A. Vieira-Coelho, T. Hussain, V. Kansra, M. P. Serrao, J. T. Guimaraes, M. Pestana, P. Soares-da-Silva, and M. F. Lokhandwala Aging, High Salt Intake, and Renal Dopaminergic Activity in Fischer 344 Rats Hypertension, October 1, 1999; 34(4): 666 - 672. [Abstract] [Full Text] [PDF]

				O. Kuchel Differential catecholamine responses to protein intake in healthy and hypertensive subjects Am J Physiol Regulatory Integrative Comp Physiol, October 1, 1998; 275(4): R1164 - R1173. [Abstract] [Full Text] [PDF]

				T. Hussain and M. F. Lokhandwala Renal Dopamine Receptor Function in Hypertension Hypertension, August 1, 1998; 32(2): 187 - 197. [Abstract] [Full Text] [PDF]

				A. Ricci, E. Bronzetti, P. Mulatero, M. Schena, F. Veglio, and F. Amenta Dopamine D3 Receptor in Peripheral Mononuclear Cells of Essential Hypertensives Hypertension, December 1, 1997; 30(6): 1566 - 1571. [Abstract] [Full Text]